RIGEL PHARMACEUTICALS INC
Develops and commercializes small-molecule drugs for hematology, cancer, and autoimmune diseases.
RIGL | NDAQ
Overview
Corporate Details
- ISIN(s):
- US7665597024
- LEI:
- Country:
- United States of America
- Address:
- 611 GATEWAY BOULEVARD, SUITE 900, 94080 SOUTH SAN FRANCISCO
- Website:
- https://www.rigel.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Rigel Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers, develops, and commercializes novel small-molecule drugs. The company's primary focus is on creating therapies for patients with hematologic disorders, cancer, and autoimmune diseases. Rigel's pipeline is centered on developing oral kinase inhibitors to address significant unmet medical needs. Its portfolio of marketed products includes TAVALISSE® (fostamatinib disodium hexahydrate) for the treatment of chronic immune thrombocytopenia, and REZLIDHIA® (olutasidenib) for patients with relapsed or refractory acute myeloid leukemia (AML).
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all RIGEL PHARMACEUTICALS INC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for RIGEL PHARMACEUTICALS INC
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for RIGEL PHARMACEUTICALS INC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
